Skip to content

Utility of Renal Biomarkers in Cirrhosis

Utility of Renal Biomarkers in Cirrhotic Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01217983
Enrollment
105
Registered
2010-10-08
Start date
2010-10-31
Completion date
2012-10-31
Last updated
2012-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ascitis, Cirrhosis

Brief summary

Evaluation of kidney function is critical in cirrhotic patients as there is a clear relationship between renal failure and prognosis. The investigators hypothesized that in this population new biomarkers of renal function could help in early detection of acute renal failure and in discrimination between renal and pre-renal causes. Finally the investigators hypothesized that such biomarkers could predict short-term outcome in this population.

Interventions

None listed

Sponsors

University Hospital, Geneva
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years * Known or suspected cirrhosis * Suspected ascitis * Informed consent signed

Exclusion criteria

* Proven multifocal hepatocellular carcinoma * Acute gastric hemorrhage (active or \< 2 weeks) * Known end-stage renal disease or on dialysis before admission * Recipients of kidney or liver transplants * Transferred from another institution

Design outcomes

Primary

MeasureTime frameDescription
Early detection of acute kidney injury in hospitalized cirrhotic patients with ascitis using new renal biomarkers30 daysAcute kidney injury will be defined using RIFLE and AKIN criteria.

Secondary

MeasureTime frame
Prediction of adverse clinical outcomes (Renal replacement therapy, transfer to ICU, all cause mortality).30 days
Discrimination between different type of AKI.30 days
Prediction of AKI developement using renal artery resistive indexes.30 days

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026